{
    "clinical_study": {
        "@rank": "132803", 
        "arm_group": [
            {
                "arm_group_label": "Arm I (B-WARM at 38 degrees C)", 
                "arm_group_type": "Experimental", 
                "description": "Patients undergo B-WARM at 38 degrees C for 2 hours."
            }, 
            {
                "arm_group_label": "Arm II (B-WARM at 39 degrees C)", 
                "arm_group_type": "Experimental", 
                "description": "Patients undergo B-WARM at 39 degrees C for 2 hours."
            }
        ], 
        "brief_summary": {
            "textblock": "This randomized pilot clinical trial studies body warming in improving blood flow and oxygen\n      delivery to tumors in patients with cancer. Heating tumor cells to several degrees above\n      normal body temperature may kill tumor cells."
        }, 
        "brief_title": "Body Warming in Improving Blood Flow and Oxygen Delivery to Tumors in Patients With Cancer", 
        "condition": [
            "Adult Primary Liver Cancer", 
            "Breast Cancer", 
            "Colon Cancer", 
            "Head and Neck Cancer", 
            "Kidney Tumor", 
            "Lung Cancer", 
            "Malignant Neoplasm", 
            "Melanoma", 
            "Ovarian Neoplasm", 
            "Soft Tissue Sarcoma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Breast Neoplasms", 
                "Neoplasms", 
                "Colonic Neoplasms", 
                "Head and Neck Neoplasms", 
                "Kidney Neoplasms", 
                "Liver Neoplasms", 
                "Lung Neoplasms", 
                "Melanoma", 
                "Ovarian Neoplasms", 
                "Sarcoma"
            ]
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. To determine the feasibility and efficacy of 2 different B-WARM regimens on altering\n      tumor blood flow in patients with a variety of malignancies.\n\n      SECONDARY OBJECTIVES:\n\n      I. To determine if duration and thermal dose of B-WARM changes duration and extent of tumor\n      blood flow changes in patients with a variety of malignancies.\n\n      II. To determine if there is a correlation between computed tomography (CT) scans and\n      optical/thermal imaging in terms of changes in blood flow and volume before and after\n      therapy.\n\n      OUTLINE: Patients are randomized to 1of 2 arms.\n\n      ARM I: Patients undergo B-WARM at 38 degrees Celsius (C) for 2 hours.\n\n      ARM II: Patients undergo B-WARM at 39 degrees C for 2 hours.\n\n      After completion of study, patients are followed up at 30 minutes, 40-88 hours, 88-264\n      hours, and 30 days."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with a variety of malignancies (i.e., melanoma, sarcoma, colon, head and\n             neck, renal, breast, lung, ovary, liver)\n\n          -  Patients must have measurable disease by CT scan\n\n          -  Have an estimated glomerular filtration rate (eGFR) (using the Cockcroft-Gault\n             equation) of more than 60 mL/min\n\n          -  Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2\n\n          -  Patients of child-bearing potential must agree to use acceptable contraceptive\n             methods (e.g., double barrier) during treatment\n\n          -  Patient or legal representative must understand the investigational nature of this\n             study and sign an Independent Ethics Committee/Institutional Review Board approved\n             written informed consent form prior to receiving any study related procedure\n\n        Exclusion Criteria:\n\n          -  History of prior myocardial infarction or arrhythmia\n\n          -  History of any condition deemed by the principal investigator to be a\n             contraindication to B-WARM therapy (e.g., skin reaction, dysregulation of\n             thermoregulation, etc)\n\n          -  All patients with transdermal patches (e.g.; fentanyl, lidoderm, scopolamine, etc)\n\n          -  Pregnant or nursing female patients\n\n          -  Unwilling or unable to follow protocol requirements\n\n          -  Any condition which in the investigator's opinion deems the patient an unsuitable\n             candidate to receive B-WARM\n\n          -  Received an investigational agent within 30 days prior to enrollment\n\n          -  Received any systemic therapy within 21 days prior to planned B-WARM therapy\n\n               -  Patients may be enrolled on study but at least 21 days should elapse prior to\n                  date of B-WARM therapy\n\n          -  Patients should not have either CT scanning or B-WARM if they have a fever at the\n             time\n\n               -  Fever should be worked up and treated as appropriate\n\n               -  Patients should be afebrile for 24 hours prior to scanning or B-WARM therapy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "90", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01896778", 
            "org_study_id": "I 229812", 
            "secondary_id": [
                "NCI-2013-01198", 
                "P30CA016056"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Arm I (B-WARM at 38 degrees C)", 
                "description": "Undergo B-WARM at 38 degrees C", 
                "intervention_name": "hyperthermia treatment", 
                "intervention_type": "Procedure", 
                "other_name": "hyperthermia"
            }, 
            {
                "arm_group_label": "Arm II (B-WARM at 39 degrees C)", 
                "description": "Undergo B-WARM at 39 degrees C", 
                "intervention_name": "hyperthermia treatment", 
                "intervention_type": "Procedure", 
                "other_name": "hyperthermia"
            }, 
            {
                "arm_group_label": [
                    "Arm I (B-WARM at 38 degrees C)", 
                    "Arm II (B-WARM at 39 degrees C)"
                ], 
                "description": "Correlative studies", 
                "intervention_name": "laboratory biomarker analysis", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "April 14, 2014", 
        "location": {
            "contact": {
                "email": "ASKRPCI@RoswellPark.org", 
                "last_name": "Roswell Park", 
                "phone": "877-275-7724"
            }, 
            "facility": {
                "address": {
                    "city": "Buffalo", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "14263"
                }, 
                "name": "Roswell Park Cancer Institute"
            }, 
            "investigator": {
                "last_name": "Anurag K. Singh", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Body Warming to Alter [Thermo] Regulation and the Microenvironment [B-WARM] Therapy: A Pilot Study", 
        "overall_official": {
            "affiliation": "Roswell Park Cancer Institute", 
            "last_name": "Anurag Singh", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary analysis will be implemented using an analysis-of-covariance (ANCOVA) model for both blood flow and blood volume.", 
            "measure": "Changes in tumor vascular (blood flow, blood volume)", 
            "safety_issue": "No", 
            "time_frame": "Baseline to 24-88 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01896778"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Changes in tumor vascular measures", 
            "safety_issue": "No", 
            "time_frame": "Baseline to 88-264 hours"
        }, 
        "source": "Roswell Park Cancer Institute", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "National Cancer Institute (NCI)", 
                    "agency_class": "NIH"
                }, 
                {
                    "agency": "Braun Foundation", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Roswell Park Cancer Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}